Das Medizinportal

Das Medizinportal

Passwort vergessen?

Bitte geben Sie Ihren Ihre E-Mail-Adresse ein. Anweisungen zum Zurücksetzen des Passworts werden Ihnen umgehend per E-Mail übermittelt.


Mikrostents für die trabekuläre mikro-invasive Glaukomchirurgie (S. 10-16)
A. Jünemann

  1. Ahmed, Ii, Katz LJ, Chang DF et al. (2014) Prospective evaluation of microinvasive glaucoma surgery with trabecular microbypass stents and prostaglandin in open-angle glaucoma. Journal of cataract and refractive surgery 40:1295-1300
  2. Arriola-Villalobos P, Martinez-De-La-Casa JM, Diaz-Valle D et al. (2012) Combined iStent trabecular micro-bypass stent implantation and phacoemulsification for coexistent open-angle glaucoma and cataract: a long-term study. The British journal of ophthalmology 96:645-649
  3. Arriola-Villalobos P, Martinez-De-La-Casa JM, Diaz-Valle D et al. (2013) Mid-term evaluation of the new Glaukos iStent with phacoemulsification in coexistent open-angle glaucoma or ocular hypertension and cataract. The British journal of ophthalmology 97:1250-1255
  4. Belovay GW, Naqi A, Chan BJ et al. (2012) Using multiple trabecular micro-bypass stents in cataract patients to treat open-angle glaucoma. Journal of cataract and refractive surgery 38:1911-1917
  5. Buchacra O, Duch S, Milla E et al. (2011) One-year analysis of the iStent trabecular microbypass in secondary glaucoma. Clinical ophthalmology 5:321-326
  6. Caprioli J, Kim JH, Friedman DS et al. (2015) Special Commentary: Supporting Innovation for Safe and Effective Minimally Invasive Glaucoma Surgery Summary of a Joint Meeting of the American Glaucoma Society and the Food and Drug Administration, Washington, DC, February 26, 2014. Ophthalmology 122:1795-1801
  7. Craven ER (2015) Trabecular micro-bypass shunt (iStent(R)): basic science, clinical, and future). Middle East African journal of ophthalmology 22:30-37
  8. Craven ER, Katz LJ, Wells JM et al. (2012) Cataract surgery with trabecular micro-bypass stent implantation in patients with mild-to-moderate open-angle glaucoma and cataract: two-year follow-up. Journal of cataract and refractive surgery 38:1339-1345
  9. Donnenfeld ED, Solomon KD, Voskanyan L et al. (2015) A prospective 3-year follow-up trial of implantation of two trabecular microbypass stents in open-angle glaucoma. Clinical ophthalmology 9:2057-2065
  10. Fea AM (2010) Phacoemulsification versus phacoemulsification with micro-bypass stent implantation in primary open-angle glaucoma: randomized double-masked clinical trial. J Cataract Refract Surg 36:407-412
  11. Fea AM, Ahmed, Ii, Lavia C et al. (2017) Hydrus microstent compared to selective laser trabeculoplasty in primary open angle glaucoma: one year results. Clinical & experimental ophthalmology 45:120-127
  12. Fea AM, Belda JI, Rekas M et al. (2014) Prospective unmasked randomized evaluation of the iStent inject versus two ocular hypotensive agents in patients with primary open-angle glaucoma. Clinical ophthalmology 8:875-882
  13. Fea AM, Consolandi G, Zola M et al. (2015) Micro-Bypass Implantation for Primary Open-Angle Glaucoma Combined with Phacoemulsification: 4-Year Follow-Up. J Ophthalmol 2015:795357
  14. Ferguson TJ, Swan R, Ibach M et al. (2017) Trabecular microbypass stent implantation with cataract extraction in pseudoexfoliation glaucoma. Journal of cataract and refractive surgery 43:622-626
  15. Fernandez-Barrientos Y, Garcia-Feijoo J, Martinez-De-La-Casa JM et al. (2010) Fluorophotometric study of the effect of the glaukos trabecular microbypass stent on aqueous humor dynamics. Investigative ophthalmology & visual science 51:3327-3332
  16. Gandolfi SA, Ungaro N, Ghirardini S et al. (2016) Comparison of Surgical Outcomes between Canaloplasty and Schlemm's Canal Scaffold at 24 Months' Follow-Up. Journal of ophthalmology 2016:3410469
  17. Gonnermann J, Bertelmann E, Pahlitzsch M et al. (2017) Contralateral eye comparison study in MICS & MIGS: Trabectome vs. iStent inject. Graefe's archive for clinical and experimental ophthalmology 255:359-365
  18. Hoeh H, Vold SD, Ahmed IK et al. (2016) Initial Clinical Experience With the CyPass Micro-Stent: Safety and Surgical Outcomes of a Novel Supraciliary Microstent. Journal of glaucoma 25:106-112
  19. Hohberger B, Monczak E, Mardin CY (2017) 26 Years of the Erlangen Glaucoma Registry: Demographic and Perimetric Characteristics of Patients Through the Ages]. Klinische Monatsblatter fur Augenheilkunde
  20. Hohberger B, Welge-Luen UC, Lammer R (2017) ICE-Syndrome: A Case Report of Implantation of a Microbypass Xen Gel Stent After DMEK Transplantation. Journal of glaucoma 26:e103-e104
  21. Katz LJ, Erb C, Carceller GA et al. (2015) Prospective, randomized study of one, two, or three trabecular bypass stents in open-angle glaucoma subjects on topical hypotensive medication. Clinical ophthalmology 9:2313-2320
  22. Klamann MK, Gonnermann J, Pahlitzsch M et al. (2015) iStent inject in phakic open angle glaucoma. Graefe's archive for clinical and experimental ophthalmology 253:941-947
  23. Leske MC, Heijl A, Hussein M et al. (2003) Factors for glaucoma progression and the effect of treatment: the early manifest glaucoma trial. Arch Ophthalmol 121:48-56
  24. Lewis RA (2014) Ab interno approach to the subconjunctival space using a collagen glaucoma stent. Journal of cataract and refractive surgery 40:1301-1306
  25. Lindstrom R, Lewis R, Hornbeak DM et al. (2016) Outcomes Following Implantation of Two Second-Generation Trabecular Micro-Bypass Stents in Patients with Open-Angle Glaucoma on One Medication: 18-Month Follow-Up. Advances in therapy 33:2082-2090
  26. Neuhann TH (2015) Trabecular micro-bypass stent implantation during small-incision cataract surgery for open-angle glaucoma or ocular hypertension: Long-term results. Journal of cataract and refractive surgery 41:2664-2671
  27. Patel I, De Klerk TA, Au L (2013) Manchester iStent study: early results from a prospective UK case series. Clinical & experimental ophthalmology 41:648-652
  28. Pfeiffer N, Garcia-Feijoo J, Martinez-De-La-Casa JM et al. (2015) A Randomized Trial of a Schlemm's Canal Microstent with Phacoemulsification for Reducing Intraocular Pressure in Open-Angle Glaucoma. Ophthalmology 122:1283-1293
  29. Saheb H, Ahmed, Ii (2012) Micro-invasive glaucoma surgery: current perspectives and future directions. Current opinion in ophthalmology 23:96-104
  30. Samuelson TW, Katz LJ, Wells JM et al. (2011) Randomized evaluation of the trabecular micro-bypass stent with phacoemulsification in patients with glaucoma and cataract. Ophthalmology 118:459-467
  31. Spiegel D, Wetzel W, Neuhann T et al. (2009) Coexistent primary open-angle glaucoma and cataract: interim analysis of a trabecular micro-bypass stent and concurrent cataract surgery. European journal of ophthalmology 19:393-399
  32. Sultan M, Blondeau P (2003) Episcleral venous pressure in younger and older subjects in the sitting and supine positions. Journal of glaucoma 12:370-373
  33. Tamm ER, Braunger BM, Fuchshofer R (2015) Intraocular Pressure and the Mechanisms Involved in Resistance of the Aqueous Humor Flow in the Trabecular Meshwork Outflow Pathways. Progress in molecular biology and translational science 134:301-314
  34. Tan SZ, Au L (2016) Manchester iStent study: 3-year results and cost analysis. Eye 30:1365-1370
  35. Vandewalle E, Zeyen T, Stalmans I (2009) The iStent trabecular micro-bypass stent: a case series. Bulletin de la Societe belge d'ophtalmologie:23-29
  36. Vold SD, Voskanyan L, Tetz M et al. (2016) Newly Diagnosed Primary Open-Angle Glaucoma Randomized to 2 Trabecular Bypass Stents or Prostaglandin: Outcomes Through 36 Months. Ophthalmol Ther 5:161-172
  37. Voskanyan L, Garcia-Feijoo J, Belda JI et al. (2014) Prospective, unmasked evaluation of the iStent(R) inject system for open-angle glaucoma: synergy trial. Advances in therapy 31:189-201
  38. Wellik SR, Dale EA (2015) A review of the iStent((R)) trabecular micro-bypass stent: safety and efficacy. Clinical ophthalmology 9:677-684

Spurenelemente und Glaukom (S. 17-20)
B. Hohberger

  1. Sommer A. Intraocular pressure and glaucoma. American journal of ophthalmology. 1989;107(2):186-8.
  2. Hohberger B, Monczak E, Mardin CY. [26 Years of the Erlangen Glaucoma Registry: Demographic and Perimetric Characteristics of Patients Through the Ages]. Klinische Monatsblatter fur Augenheilkunde. 2017.
  3. Gupta N, Yucel YH. Glaucoma as a neurodegenerative disease. Current opinion in ophthalmology. 2007;18(2):110-4.
  4. Sacca SC, Pascotto A, Camicione P, Capris P, Izzotti A. Oxidative DNA damage in the human trabecular meshwork: clinical correlation in patients with primary open-angle glaucoma. Archives of ophthalmology. 2005;123(4):458-63.
  5. Izzotti A, Cartiglia C, De Flora S, Sacca S. Methodology for evaluating oxidative DNA damage and metabolic genotypes in human trabecular meshwork. Toxicology mechanisms and methods. 2003;13(3):161-8.
  6. Terman A, Gustafsson B, Brunk UT. The lysosomal-mitochondrial axis theory of postmitotic aging and cell death. Chemico-biological interactions. 2006;163(1-2):29-37.
  7. Ugarte M, Osborne NN. Zinc in the retina. Progress in neurobiology. 2001;64(3):219-49.
  8. Rahal A, Kumar A, Singh V, Yadav B, Tiwari R, Chakraborty S, et al. Oxidative stress, prooxidants, and antioxidants: the interplay. BioMed research international. 2014;2014:761264.
  9. Clark LC, Combs GF, Jr., Turnbull BW, Slate EH, Chalker DK, Chow J, et al. Effects of selenium supplementation for cancer prevention in patients with carcinoma of the skin. A randomized controlled trial. Nutritional Prevention of Cancer Study Group. Jama. 1996;276(24):1957-63.
  10. Combs GF, Jr., Clark LC, Turnbull BW. Reduction of cancer risk with an oral supplement of selenium. Biomedical and environmental sciences : BES. 1997;10(2-3):227-34.
  11. Rotruck JT, Pope AL, Ganther HE, Swanson AB, Hafeman DG, Hoekstra WG. Selenium - Biochemical Role as a Component of Glutathione Peroxidase. Science. 1973;179(4073):588-90.
  12. DeToma AS, Dengler-Crish CM, Deb A, Braymer JJ, Penner-Hahn JE, van der Schyf CJ, et al. Abnormal metal levels in the primary visual pathway of the DBA/2J mouse model of glaucoma. Biometals : an international journal on the role of metal ions in biology, biochemistry, and medicine. 2014;27(6):1291-301.
  13. Lee SH, Kang EM, Kim GA, Kwak SW, Kim JM, Bae HW, et al. Three Toxic Heavy Metals in Open-Angle Glaucoma with Low-Teen and High-Teen Intraocular Pressure: A Cross-Sectional Study from South Korea. PloS one. 2016;11(10).
  14. Ceylan OM, Demirdogen BC, Mumcuoglu T, Aykut O. Evaluation of Essential and Toxic Trace Elements in Pseudoexfoliation Syndrome and Pseudoexfoliation Glaucoma. Biol Trace Elem Res. 2013;153(1-3):28-34.
  15. Akyol N, Deger O, Keha EE, Kilic S. Aqueous-Humor and Serum Zinc and Copper Concentrations of Patients with Glaucoma and Cataract. Brit J Ophthalmol. 1990;74(11):661-2.
  16. Lin SC, Singh K, Lin SC. Association Between Body Levels of Trace Metals and Glaucoma Prevalence. JAMA ophthalmology. 2015;133(10):1144-50.
  17. Ferreira SM, Lerner SF, Brunzini R, Evelson PA, Llesuy SF. Oxidative stress markers in aqueous humor of glaucoma patients. American journal of ophthalmology. 2004;137(1):62-9.
  18. Duffield-Lillico AJ, Reid ME, Turnbull BW, Combs GF, Jr., Slate EH, Fischbach LA, et al. Baseline characteristics and the effect of selenium supplementation on cancer incidence in a randomized clinical trial: a summary report of the Nutritional Prevention of Cancer Trial. Cancer epidemiology, biomarkers & prevention: a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology. 2002;11(7):630-9.
  19. Hohberger B, Chaudhri MA, Michalke B, Lucio M, Nowomiejska K, Schlotzer-Schrehardt U, et al. Levels of aqueous humor trace elements in patients with open-angle glaucoma. J Trace Elem Med Biol. 2018;45:150-5.
  20. Oteiza PI. Zinc and the modulation of redox homeostasis. Free radical biology & medicine. 2012;53(9):1748-59.
  21. Gonzalez P, Epstein DL, Borras T. Genes upregulated in the human trabecular meshwork in response to elevated intraocular pressure. Investigative ophthalmology & visual science. 2000;41(2):352-61.
  22. Rogers BS, Symons RC, Komeima K, Shen J, Xiao W, Swaim ME, et al. Differential sensitivity of cones to iron-mediated oxidative damage. Investigative ophthalmology & visual science. 2007;48(1):438-45.
  23. Wang SY, Singh K, Lin SC. Glaucoma prevalence and the intake of iron and calcium in a population-based study. Current eye research. 2013;38(10):1049-56.

Homocystein bei der Glaukomerkrankung – ein Missing Link? (S. 21-26) CME
A. Jünemann

  1. Jünemann A Medicinal glaucoma therapy. What can we learn from large randomized clinical trials? Der Ophthalmologe 2013: 110: 1134-1148
  2. Hankey GJ, Eikelboom JW. Homocysteine and vascular disease. Lancet 1999; 354:407-413
  3. Watkins D, Rosenblatt DS (1989) Functional methionine synthase deficiency (cblE and cblG): clinical and biochemical heterogeneity. Am J Med Genet 34:427-434
  4. Rozen R (2000) Genetic modulation of homocysteinemia. Semin Thromb Hemost 26:255-261
  5. Frosst P, Blom HJ, Milos R et al (1995) A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase. Nat Genet 10:111-113
  6. Rady PL, Szucs S, Grady J et al (2002) Genetic polymorphisms of methylenetetrahydrofolate reductase (MTHFR) and methionine synthase reductase (MTRR in ethnic populations in Texas; a report of a novel MTHFR polymorphic site, G1793A. Am J Med Genet 107:162-168
  7. Škovierová H, Vidomanová E, Mahmood S, et al. The Molecular and Cellular Effect of Homocysteine Metabolism Imbalance on Human Health. Int J Mol Sci 2016; 17: 1733-1751
  8. Seshadri S, Beiser A, Selhub J et al. Plasma homocysteine as a risk factor for dementia and Alzheimer’s disease. N Engl J Med 2002; 346: 476–483
  9. Joosten E, Lesaffre E, Riezler R. Are different reference intervals for methylmalonic acid and total homocysteine necessary in elderly people? Eur J Haematol 1996; 57: 222–226
  10. Rasmussen K, Moller J, Lyngbak M et al. Age- and gender-specific reference intervals for total homocysteine and methylmalonic acid in plasma before and after vitamin supplementation. Clin Chem 1996; 42: 630–636
  11. Ubbink JB, Becker PJ, Vermaak WJ et al .Results of B-vitamin supplementation study used in a prediction model to define a reference range for plasma homocysteine. Clin Chem 1995; 41: 1033–1037
  12. Nygard O, Nordrehaug JE, Refsum H, et al. Plasma homocysteine levels and mortality in patients with coronary artery disease. N Engl J Med 1997; 337: 230–236
  13. Vessani RM, Ritch R, Liebmann JM et al. Plasma homocysteine is elevated in patients with exfoliation syndrome. Am J Ophthalmol 2003; 136: 41–46
  14. Hankey GJ, Eikelboom JW. Homocysteine and vascular disease. Lancet 1999; 354:407-413
  15. Andreotti F, Burzotta F, Manzoli A, Robinson K (2000) Homocysteine and risk of cardiovascular disease. J Thromb Thrombolysis 9:13-21
  16. Meleady R, Graham I. Plasma homocysteine as a cardiovascular risk factor: causal, consequential, or of no consequence? Nutr Rev 1999; 57: 299-305
  17. Bleich S, Junemann A, von Ahsen N, et al. Homocysteine and risk of open-angle glaucoma. J Neural Trans 2002;109: 1499–1504
  18. Roedl JB, Bleich S, Reulbach U et al. Vitamin deficiency and hyperhomocysteinemia in pseudoexfoliation glaucoma. J Neur Trans (Vienna, Austria) 2007; 114: 571–575
  19. Roedl JB, Bleich S, Schlotzer-Schrehardt U et al. Increased homocysteine levels in tear fluid of patients with primary open-angle glaucoma. Ophthalmic Res 2008; 40: 249–256
  20. Wang G, Medeiros FA, Barshop BA et al. Total plasma homocysteine and primary open-angle glaucoma. Am J Ophthalmol 2004; 137: 401–406
  21. Altintas O, Maral H, Yuksel N et al. Homocysteine and nitric oxide levels in plasma of patients with pseudoexfoliation syndrome, pseudoexfoliation glaucoma, and primary open-angle glaucoma. Graefes Arch Clin Exp Ophthalmol 2005; 243: 677–683
  22. Cumurcu T, Sahin S, Aydin E. Serum homocysteine, vitamin B12 and folic acid levels in different types of glaucoma. BMC Ophthalmol 2006; 6: 6
  23. Turgut B, Kaya M, Arslan S. Levels of circulating homocysteine, vitamin B6,vitamin B12, and folate in different types of open-angle glaucoma Clin Intervent Aging 2010; 5: 133–139
  24. Tranchina L, Centofanti M, Oddone F et al. Levels of plasma homocysteine in pseudoexfoliation glaucoma. Graefes Arch Clin Exp Ophthalmol 2011; 249: 443–448
  25. Zacharaki F, Hadjigeorgiou GM, Koliakos GG et al. Plasma homocysteine and genetic variants of homocysteine metabolism enzymes in patients from central Greece with primary open-angle glaucoma and pseudoexfoliation glaucoma. Clin Ophthalmology 2014:8 1819–1825
  26. Turaçli ME, Tekeli O, Özdemir F et al. Methylenetetrahydrofolate reductase 677 C-T and homocysteine levels in Turkish patients with pseudoexfoliation. Clin Exp Ophthalmol 2005; 33: 505–508
  27. Türkcü FM, Köz OG, Yarangümeli A et al. Plasma Homocysteine, Folic Acid, and Vitamin B12 Levels in Patients With Pseudoexfoliation Syndrome, Pseudoexfoliation Glaucoma, and Normotensive Glaucoma. Medicina (Kaunas) 2013; 49: 214-218
  28. Xu F, Zhao X, Zeng SM et al, Homocysteine, B Vitamins, Methylenetetrahydrofolate Reductase Gene, and Risk of Primary Open-Angle Glaucoma. A Meta-analysis. Ophthalmology 2012; 119: 2493–2499
  29. Xu F, Zhang L, Li M. Plasma homocysteine, serum folic acid, serum vitamin B12, serum vitamin B6, MTHFR and risk of pseudoexfoliation glaucoma: a meta-analysis. Graefes Arch Clin Exp Ophthalmol 2012; 250: 1067–1074
  30. Clement CI, Goldberg I. Methylenetetrahydrofolate reductase 677 C-T and homocysteine levels in Turkish patients with pseudoexfoliation. Clin Exp Ophthalmol 2006; 34: 500–504
  31. Li J, Xu F, Zeng R et al. Plasma Homocysteine, Serum Folic Acid, Serum Vitamin B12, Serum Vitamin B6, MTHFR, and Risk of Normal-Tension Glaucoma. J Glaucoma 2016; 25: e94–e9
  32. Bleich S, Roedl J, Von Ahsen N et al. Elevated homocysteine levels in aqueous humor of patients with pseudoexfoliation glaucoma. Am J Ophthalmol 2004; 138: 162–164
  33. Lee JY, Kim JM, Kim IT et al. Relationship between Plasma   Homocysteine Level and Glaucomatous Retinal Nerve Fiber Layer Defect. Current Eye Research 2017, DOI: 10.1080/02713683.2016.1257728
  34. Junemann AGM, von Ahsen N, Reulbach U, et al. C677T variant in the methylentetrahydrofolate reductase gene is a genetic risk factor for primary open-angle glaucoma. Am J Ophthalmol 2005; 139: 721–723
  35. Roedl JB, Bleich S, Reulbach U et al. Homocysteine in tear fluid of patients with pseudoexfoliation glaucoma. J Glaucoma 2007; 16: 234–239
  36. Martí-Carvajal AJ, Solà I, Lathyris D et al. Homocysteine-lowering interventions for preventing cardiovascular events (Review). Cochrane Database of Systematic Reviews 2017, Issue 8. Art. No.: CD006612. DOI: 10.1002/14651858.CD006612.pub5
  37. Park JH, Saposnik G, Ovbiagele B et al. Effect of B-vitamins on stroke risk among individuals with vascular disease who are not on antiplatelets: A meta-analysis. Int J Stroke 2016; 11: 206–211
  38. Seshadri S. Homocysteine and the Risk of Dementia. Clin Chem 2012; 58: 1059–1060

Katarakt-Operation bei enger Pupille und Floppy Iris: Strategien zum Erfolg
(S. 27-29)
A. Mirshahi

  1. Shingleton BJ, Campbell CA, O'Donoghue MW. Effects of pupil stretch technique during phacoemulsification on postoperative vision, intraocular pressure, and inflammation. J Cataract Refract Surg. 2006 Jul;32(7):1142-5.
  2. Hashemi H, Seyedian MA, Mohammadpour M. Small pupil and cataract surgery. Curr Opin Ophthalmol. 2015 Jan;26(1):3-9.
  3. Malyugin BE. Recent advances in small pupil cataract surgery. Curr Opin
    Ophthalmol. 2018 Jan;29(1):40-47.
  4. Abdel-Aziz S, Mamalis N. Intraoperative Floppy Iris syndrome. Curr Opin
    Ophthalmol. 2009 Jan;20(1):37-41.

Update – Aus den Unternehmen

Novartis: Anti-VEGF-Therapie: Schlüssel zum Erfolg (S. 35/36)

  1. Brown D et al. for the ANCHOR Study Group. Ranibizumab versus Verteporfin Photodynamic Therapy for Neovascular Age-Related Macular Degeneration: Two-Year Results of the  ANCHOR Study. Ophthalmology 2009, 116: 57–65.
  2. Rosenfeld PJ et al. for the  MARINA Study Group. Ranibizumab for Neovascular Age-Related Macular Degeneration. N Engl J Med 2006; 355: 1419–1431.
  3. Holz FG et al. Multi-country real-life experience of anti-vascular endothelial growth factor therapy for wet age-related macular degeneration. Br J Ophthalmol 2015; 99: 220–226.
  4. Ziemssen F et al. Verzögerung des Behandlungsbeginns um mehr als 2 Wochen – Relevanz für möglichen Visusgewinn nach Anti-VEGF-Therapie unter Real-Life-Bedingungen (Interimanalyse der prospektiven OCEAN-Studie). Ophthalmologe 2016; 113: 143–151.
  5. eiss M et al. Compliance and adherence of patients with diabetic macular edema to intravitreal anti-vascular endothelial growth factor therapy in daily practice. Retina 2017 [Epub ahead of print].

AbbVie: TNF-Blocker in interdisziplinären Leitlinie aufgenommen (S. 36)

  1. Interdisziplinäre Leitlinie zur Diagnostik und antientzündlichen Therapie der Uveitis bei juveniler idiopathischer Arthritis; augeninfo.de/leit/leit14a.pdf (Download am 13.03.2018)
  2. Humira 20 mg/0,2 ml Fachinformation, Stand März 2018

Bayer: EMNID-Umfrage: AMD kaum bekannt (S. 36/37)

  1. Kantar EMNID: Bedeutung des Sehens für Menschen mit AMD und ältere Personen 70+; 2017
  2.  Eleftheriadou M et al.; Long-Term Outcomes of Aflibercept Treatment for Neovascular Age-Related Macular Degeneration in a Clinical Setting. Am J Ophthalmol 2017; 174:160-168.
  3. Framme C et al.; Aflibercept for Patients with Neovascular Age-Related Macular Degeneration in Routine Clinical Practice in Germany Twelve-Month Outcomes of PERSEUS doi.org/10.1016/j.oret.2017.09.017